April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Difference of intraocular pressure lowering effects among 3 Prostaglandin analogs for korean glaucoma and ocular hypertension patients
Author Affiliations & Notes
  • Seung Jae Lee
    Ophthalmology, National Medical Center, Seoul, Republic of Korea
  • Youngdon Kim
    Ophthalmology, National Medical Center, Seoul, Republic of Korea
  • Haksu Kyung
    Ophthalmology, National Medical Center, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Seung Jae Lee, None; Youngdon Kim, None; Haksu Kyung, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 552. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seung Jae Lee, Youngdon Kim, Haksu Kyung, Ophthalmologic department, National Medical Center, Seoul, South Korea; Difference of intraocular pressure lowering effects among 3 Prostaglandin analogs for korean glaucoma and ocular hypertension patients. Invest. Ophthalmol. Vis. Sci. 2014;55(13):552.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare intraocular pressure(IOP) lowering effects of tafluprost, travoprost, bimatoprost respectively for korean glaucoma patients.

Methods: Seventy eight patients, 147 eyes, diagnosed with normal tension glaucoma(NTG), ocular hypertension(OHT), or primary open-angle glaucoma(POAG), received 0.0015% tafluprost, 0.004% travoprost or 0.01% bimatoprost respectively once daily. We compared and analyzed IOP and the change of IOP at baseline, after a week and after a month.

Results: Of all 147 eyes, there were 72 eyes of NTG, 35 eyes of OHT, 7 eyes of POAG, and 10 eyes of other glaucoma in tafluprost group. There were 24 eyes of NTG, 2 eyes of POAG, and 7 eyes of other glaucoma in travoprost group. There were 14 eyes of NTG, 4 eyes of POAG, and 2 eyes of other glaucoma in bimatoprost group. In tafluprost group, the average IOP was 16.2 ± 3.2 mmHg at baseline, 12.5 ± 2.6 mmHg (p<0.0001) after 1 week, and 12.4 ± 2.8 mmHg(p<0.0001) after 1 month. In travoprost group, the average IOP was 15.1 ± 2.2 mmHg at baseline, 11.0 ± 2.7 mmHg (p<0.0001) after 1 week, and 12.7 ± 2.2 mmHg (p=0.001) after 1 month. In bimatoprost group the IOP was 16.5 ± 2.8 mmHg at baseline, 11.9 ± 2.2mmHg(p<0.0001) after 1 week, and 13.7 ± 3.5 mmHg (p<0.0001) after 1 month, which all showed statistically significant IOP reduction. No meaningful correlation bewteen baseline IOP and the change of IOP was shown in the travoprost group (p=0.191, r=0.234) and bimatoprost group (p=0.395, r=0.201). However in tafluprost group (p=0.03, r=0.305), as the baseline IOP was higher, the change of IOP was higher significantly.

Conclusions: Tafluprost, travoprost and bimatoprost were all effective in IOP lowering effects until one month for korean glaucoma and ocular hypertension patients. Travoprost and bimatoprost showed consistent IOP reduction regardless of baseline IOP. Otherwise in tafluprost group, as the baseline IOP was higher, the change of IOP was higher significantly.

Keywords: 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×